EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, Myeloma13 October 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, Myeloma22 September 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, Myeloma18 September 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, Myeloma22 August 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, Myeloma14 August 2023
Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern EuropeAccess, Myeloma25 June 2023
The European Medicines Agency (EMA) approves Melflufen (Pepaxti®) for the treatment of refractory myelomaAccess, Myeloma30 August 2022
